Bryan, Garnier & Co's News

Genmab: Daratumumab caught everyone's eye once again

BUY, Fair Value Under Review
News published on
June Monday 13, 2016


Details from the POLLUX study (which evaluated daratumumab in combination with Celgene’s Revlidmid (lenalidomide) and dexamethasone in relapsed/refractory patients with multiple myeloma) were presented yesterday at the EHA meeting; and let’s say the data were simply outstanding… And we will update our sales estimates accordingly. For the time being, we put our FV under (positive) review while reiterating our BUY recommendation.

Click here to download


For more information, please contact marekting@bryangarnier.com